A Phase II Study of Everolimus in Patients with FDG-PET Positive Intermediate Grade (Ki67 3-20%) Pancreatic Neuroendocrine Tumor Abstract #1158

Introduction: The RADIANT-3 trial showed Everolimus (EV), as active in patients (pts) with progressive well/intermediate grade PNETs. Intermediate/grade 2 (Ki67 3-20%) PNETs have variable biology. FDG-PET avidity is an independent negative factor for survival, consistent with aggressive disease biology- but such imaging is not used to select treatment as in the case of the RADIANT 3 trial.
Aim(s): Assess the activity of EV as first-line therapy in patients with FDG-avid intermediate/grade 2 PNETs.
Materials and methods: Eligible pts had newly diagnosed FDG-PET-avid grade 2 advanced PNET with measurable/ evaluable disease. ECOG PS 0-2. Adequate organ function. No prior systemic therapy for PNETs. Pts received EV 10mg po daily until disease progression. Pts were staged every 12 weeks with structural imaging/FDG and Gal-DOTA PET. Primary endpoint was PFS at 6 months. PET/structural imaging response rate, response duration, toxicity and QOL were also measured.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: ASSOC PROF Michael Michael
Keywords: everolimus, FDG-PET

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result